EP1855523A4 - Resistance a l'insuline et la leptine avec de l'hyperletptinemie dans des souris deficientes en recepteur d'androgene - Google Patents

Resistance a l'insuline et la leptine avec de l'hyperletptinemie dans des souris deficientes en recepteur d'androgene

Info

Publication number
EP1855523A4
EP1855523A4 EP06717647A EP06717647A EP1855523A4 EP 1855523 A4 EP1855523 A4 EP 1855523A4 EP 06717647 A EP06717647 A EP 06717647A EP 06717647 A EP06717647 A EP 06717647A EP 1855523 A4 EP1855523 A4 EP 1855523A4
Authority
EP
European Patent Office
Prior art keywords
hyperleptinemia
insulin
androgen receptor
mice lacking
leptin resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06717647A
Other languages
German (de)
English (en)
Other versions
EP1855523A2 (fr
Inventor
Chawnshang Chang
Hung-Yun Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of EP1855523A2 publication Critical patent/EP1855523A2/fr
Publication of EP1855523A4 publication Critical patent/EP1855523A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP06717647A 2005-01-07 2006-01-06 Resistance a l'insuline et la leptine avec de l'hyperletptinemie dans des souris deficientes en recepteur d'androgene Withdrawn EP1855523A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64212905P 2005-01-07 2005-01-07
PCT/US2006/000474 WO2006074378A2 (fr) 2005-01-07 2006-01-06 Resistance a l'insuline et la leptine avec de l'hyperletptinemie dans des souris deficientes en recepteur d'androgene

Publications (2)

Publication Number Publication Date
EP1855523A2 EP1855523A2 (fr) 2007-11-21
EP1855523A4 true EP1855523A4 (fr) 2010-06-23

Family

ID=36648219

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06717647A Withdrawn EP1855523A4 (fr) 2005-01-07 2006-01-06 Resistance a l'insuline et la leptine avec de l'hyperletptinemie dans des souris deficientes en recepteur d'androgene

Country Status (4)

Country Link
EP (1) EP1855523A4 (fr)
AU (1) AU2006203870A1 (fr)
CA (1) CA2596783A1 (fr)
WO (1) WO2006074378A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012394A2 (fr) * 2001-07-27 2003-02-13 University Of Rochester Animaux transgeniques a inactivation du recepteur androgene
WO2003100028A2 (fr) * 2002-05-28 2003-12-04 University Of Rochester Doubles inactivations de tr2, tr4 et tr2/tr4 et utilisations associees

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1456400A4 (fr) * 2001-12-19 2005-09-14 Exelixis Inc Modulation de la signalisation des recepteurs de l'insuline par ciblage de genes de facl (acyl-coa synthetase))

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012394A2 (fr) * 2001-07-27 2003-02-13 University Of Rochester Animaux transgeniques a inactivation du recepteur androgene
WO2003100028A2 (fr) * 2002-05-28 2003-12-04 University Of Rochester Doubles inactivations de tr2, tr4 et tr2/tr4 et utilisations associees

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALEVIZAKI M ET AL: "The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men.", CLINICAL ENDOCRINOLOGY DEC 2003 LNKD- PUBMED:14974917, vol. 59, no. 6, December 2003 (2003-12-01), pages 749 - 755, XP002581156, ISSN: 0300-0664 *
FAN WUQIANG ET AL: "Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion", DIABETES, vol. 54, no. 4, April 2005 (2005-04-01), pages 1000 - 1008, XP002581155, ISSN: 0012-1797 *
MAYES J S ET AL: "Direct effects of sex steroid hormones on adipose tissues and obesity.", OBESITY REVIEWS : AN OFFICIAL JOURNAL OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF OBESITY NOV 2004 LNKD- PUBMED:15458395, vol. 5, no. 4, November 2004 (2004-11-01), pages 197 - 216, XP002581154, ISSN: 1467-7881 *
SATO TAKASHI ET AL: "Late onset of obesity in male androgen receptor-deficient (AR KO) mice.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 3 JAN 2003 LNKD- PUBMED:12480537, vol. 300, no. 1, 3 January 2003 (2003-01-03), pages 167 - 171, XP002581152, ISSN: 0006-291X *
ZITZMANN M ET AL: "The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men.", DIABETOLOGIA JAN 2003 LNKD- PUBMED:12637980, vol. 46, no. 1, January 2003 (2003-01-01), pages 31 - 39, XP002581153, ISSN: 0012-186X *

Also Published As

Publication number Publication date
WO2006074378A3 (fr) 2007-03-08
WO2006074378A2 (fr) 2006-07-13
CA2596783A1 (fr) 2006-07-13
AU2006203870A1 (en) 2006-07-13
EP1855523A2 (fr) 2007-11-21

Similar Documents

Publication Publication Date Title
Stanovich RATIONAL AND IRRATIONAL THOUGHT
IL237314A0 (en) Modified insulin polypeptides and their uses
EP2286419A4 (fr) Éléments résistifs et de protection dans le moule
GB2445445A8 (en) Integrated Hardware and Software User Interface
GB2425816B (en) Tailing in and stabbing device
EP1627321A4 (fr) Definition de documents comprenant des parties qui peuvent etre selectionnees et/ou sequencees
EP2370472A4 (fr) Conjugués de leptine et d'analogues de leptine et leurs applications
EP2102237A4 (fr) Facteur ix humain recombinant et utilisation de celui-ci
GB2492703B (en) Bootstrapper and software download manager
EP2042853A4 (fr) Analyseur et son utilisation
IL207096A0 (en) Modified leptin polypeptides and their uses
WO2006121921A8 (fr) Dispositif et procede de perfusion a partie jetable
EP2023944A4 (fr) Prolifération de cellules pré-b et leucémie lymphoblastique/lymphome de haut grade chez des souris transgéniques mir155
ZA201001442B (en) Combination therapy with type i and type ii anti-cd20 antibodies
TWI360557B (en) Resin composition and its use
EP2000483A4 (fr) Proteine de fusion du recepteur du vegf et son utilisation
GB2456974B (en) Valve made from two materials and writing utensil with retractable tip incorporating same
TWI348716B (en) Resistive component and making method thereof
TWM308688U (en) Cushion and chair equipped with it
PL393049A1 (pl) Klocek i tuleja z funkcją blokowania obracania
IL197702A0 (en) Anti-idiotype conjugate and its use as a standard in an immunassay
HK1187352A1 (en) Anti-ephrinb2 antibodies and methods using same ephrinb2
EP1979827A4 (fr) Procédé d'interaction avec un utilisateur et terminal associé
EP2043748A4 (fr) Composant de canne et de poignée
EP2138192A4 (fr) Agent utilisé pour améliorer la résistance d'un liposome contre un constituant biologique et liposome modifié avec ledit agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070720

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100525

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100201